VirologyNews.net

Virology Xagena

XagenaNewsletter
Xagena Mappa
Medical Meeting
Dermabase.it

Outcomes of Hydroxychloroquine usage in United States veterans hospitalized with Covid-19


Despite limited and conflicting data on the use of Hydroxychloroquine in patients with Covid-19, the FDA ( U.S. Food and Drug Administration ) has authorized the emergency use of this drug when clinical trials are unavailable or infeasible.
Hydroxychloroquine, alone or in combination with Azithromycin, is being widely used in Covid-19 therapy based on anecdotal and limited observational evidence.

Researchers have performed a retrospective analysis of data from patients hospitalized with confirmed SARSCoV-2 infection in all United States Veterans Health Administration medical centers until April 11, 2020.
Patients were categorized based on their exposure to Hydroxychloroquine alone ( HC ) or with Azithromycin ( HC+AZ ) as treatments in addition to standard supportive management for Covid-19.

The two primary outcomes were death and the need for mechanical ventilation.

Researchers have determined the association between treatment and the primary outcomes using competing risk hazard regression adjusting for clinical characteristics via propensity scores.
Discharge and death were taken into account as competing risks and subdistribution hazard ratios are presented.

A total of 368 patients were evaluated ( HC, n=97; HC+AZ, n=113; no HC, n=158 ).

Rates of death in the HC, HC+AZ, and no HC groups were 27.8%, 22.1%, 11.4%, respectively.

Rates of ventilation in the HC, HC+AZ, and no HC groups were 13.3%, 6.9%, 14.1%, respectively.

Compared to the no HC group, the risk of death from any cause was higher in the HC group ( adjusted hazard ratio [ aHR ], 2.61; 95% CI, 1.10 to 6.17; P=0.03 ) but not in the HC+AZ group ( aHR, 1.14; 95% CI, 0.56 to 2.32; P=0.72 ).

The risk of ventilation was similar in the HC group ( aHR, 1.43; 95% CI, 0.53 to 3.79; P=0.48) and in the HC+AZ group ( aHR, 0.43; 95% CI, 0.16 to 1.12; P=0.09 ), compared to the no HC group.

In conclusion, in this trial researchers found no evidence that use of Hydroxychloroquine, either with or without Azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with Covid-19.
An association of increased overall mortality was identified in patients treated with Hydroxychloroquine alone.
These findings highlight the importance of awaiting the results of ongoing prospective, randomized, controlled studies before widespread adoption of these drugs. ( Xagena )

Magagnoli J et al, MedRxiv, 2020

XagenaMedicine_2020



Indietro